| Literature DB >> 26729828 |
Si Xuan Koo1, Sock Hoai Chan2, Joanne Ngeow2.
Abstract
A Chinese man who had undergone a curative high anterior resection for sigmoid cancer was administrated XELOX (capecitabine and oxaliplatin) as postoperative adjuvant chemotherapy. He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment. Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS. 2016 BMJ Publishing Group Ltd.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26729828 PMCID: PMC4716373 DOI: 10.1136/bcr-2015-212978
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X